PRENETICS HOLDING COMPANY LIMITED

NASDAQ: PRENW (Prenetics Holding Company Limited)

最近更新时间: 1小时之前

0.018

0.00 (36.15%)

前收盘价格 0.013
收盘价格 0.022
成交量 3,102
52周波幅
0.012 (-32%) — 0.018 (0%)
营业毛利率 -115.91%
营业利益率 (TTM) -61.41%
稀释每股收益 (EPS TTM) -11.04
季度收入增长率 (YOY) 169.90%
总债务/股东权益 (D/E MRQ) 3.20%
流动比率 (MRQ) 2.07
营业现金流 (OCF TTM) -28.87 M
杠杆自由现金流 (LFCF TTM) -9.90 M
资产报酬率 (ROA TTM) -14.52%
股东权益报酬率 (ROE TTM) -28.48%

市场趋势

短期 中期
行业 Diagnostics & Research (US) 混合的 看涨
Diagnostics & Research (全球的) 混合的 看涨
股票 Prenetics Holding Company Limited - -

AIStockmoo 评分

-0.3
分析师共识 0.0
内部交易活动 NA
价格波动 -1.0
技术平均移动指标 0.0
技术振荡指标 0.0
平均 -0.25

相关股票

股票 市值 DY P/E(TTM) P/B
PRENW - - - -
BLLN 3 B - 530.50 7.40
GRAL 3 B - - 0.900
BNR 179 M - - 2.30
ADVB 10 M - 1.76 0.820
IDXX 46 B - 44.04 28.00

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

部门 Healthcare
行业 Diagnostics & Research

所有权

姓名 日期 持有股份
Maso Capital Partners Ltd 30 Sep 2025 49,015

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票